Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1835 results
February 2020
-
In The News
Novartis CEO Vasant Narasimhan on building trust with society
Vas Narasimhan, CEO of Novartis, and CNBC’s Meg Tirrell joins “Closing Bell” in an exclusive interview at the JPMorgan Healthcare Conference. -
In The News
Novartis Pharmaceuticals head on chief, Marie-France Tschudin on rethinking the drug-launch formula
Tschudin talks with FiercePharma at the J.P. Morgan Healthcare Conference.about a “value-based approach” to drug launches.
January 2020
-
Key Release
Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines
Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicinesAcquired portfolio complements… -
Press Release
Novartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitis
New Cosentyx® (secukinumab) US label to include 300 mg up-titration option is based on Phase III MEASURE 3 study results in ankylosing spondylitis (AS)1 Label update provides clinicians with… -
Key Release
Novartis erzielt 2019 ein starkes Umsatzwachstum, Margen-steigerungen und bahnbrechende Innovationen mit der Markt¬einführung fünf neuer Wirkstoffe
Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von Cosentyx (USD 3,6 … -
Key Release
Novartis a réalisé en 2019 une forte croissance de son chiffre d’affaires, une augmentation de sa marge et une percée dans l’innovation en lançant cinq nouvelles entités moléculaires
Hausse du chiffre d’affaires net des activités poursuivies1 de 9% sur l’exercice entier (tcc2, +6% USD): Pharmaceuticals: cette unité opérationnelle progresse de 12% (tcc), sous l’impulsion de… -
Key Release
Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
Full year net sales for continuing operations1 up 9% (cc2, +6% USD): Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and… -
Featured News
Novartis at the World Economic Forum Annual Meeting Davos 2020
From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.
-
Press Release
Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent… -
Featured News
Novartis at J.P Morgan 2020
From January 13-16 2020, Novartis attended the J.P Morgan Healthcare Conference in San Francisco.
-
Story Discovery
Sourcing innovation, strategically
Phil Gotwals talks about his vision for the future of business development for research.
-
Press Release
Novartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria
Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly higher affinity than current standard of care Xolair (omalizumab)1 …